Meisam Naeimi Kararoudi

Contact Information

Call us at: (614) 355-1613

Center for Childhood Cancer700 Children’s DriveColumbus, OH 43205 (map)

Learn more about Meisam Naeimi Kararoudi

Research

Lab(s)

Center for Childhood Cancer

Dr. Naeimi Kararoudi is developing novel gene edited immune cells such as NK cells and T-cells for cancer immunotherapy. As director of the CRISPR/Gene editing core he helps investigators with their CRISPR gene editing in a verity of cells and applications. Publications

                  Naeimi Kararoudi M, Nagai Y, Elmas E, de Souza Fernandes Pereira M, Ali SA, Imus PH, Wethington D, Borrello IM, Lee DA, Ghiaur G. CD38 deletion of human primary NK cells eliminates daratumumab-induced fratricide and boosts their effector activity. Blood. 2020 Nov 19; 136: 2416-2427.

                


                  Naeimi Kararoudi M, Dolatshad H, Trikha P, Hussain SA, Elmas E, Foltz JA, Moseman JE, Thakkar A, Nakkula RJ, Lamb M, Chakravarti N, McLaughlin KJ, Lee DA. Generation of Knock-out Primary and Expanded Human NK Cells Using Cas9 Ribonucleoproteins. J Vis Exp. 2018 Jun 14;  

View More Publications

Biography

Meisam Naeimi Kararoudi, DVM, PhD, is a research assistant professor of pediatrics at The Ohio State University College of Medicine. He is also the director of CRISPR/Gene editing Core and a principal investigator in the Center for Childhood Cancer at Nationwide Children’s Hospital. He received his veterinary surgery degree from Iran. He obtained his PhD from the University of Perugia, Italy and was trained as an Erasmus scholar at the University of Oxford, UK. Being a veterinary surgeon, immunologist and genetic engineer brought him to Sweden where he used CRISPR/Cas9 to decrease rejection after transplantation of tissue engineered organs at Sahlgrenska University Hospital. During this period, he also worked in SciLifeLab as a visiting Post-Doc to use genetic modification in cancer-related projects. During his postdoc at Dr. Dean Lee’s laboratory, he developed a method to genetically modify the hard-to-transfect human Natural Killer cells using CRISPR, and identified novel approaches to enhance their cytotoxicity and to target cancers via chimeric antigen receptors.

Academic and Clinical Areas

Center for Childhood Cancer

Principal Investigator

Primary Department

Center for Childhood Cancer

Education

Date of Appointment at Nationwide Children’s Hospital: 10/02/2017

Postdoctoral Training

Nationwide Children’s Hospital

Date Completed: 12/31/2020

Graduate School

University of Perugia

Date Completed: 12/31/2017

Graduate School

University of Oxford

Date Completed: 12/31/2015

Medical School

Islamic Azad University, Tabriz Branch

Date Completed: 12/31/2011

Contact Information

Center for Childhood Cancer

Call us at: (614) 355-1613

                    700 Children's DriveColumbus, OH 43205 (map)

Contact Information

Call us at: (614) 355-1613

Center for Childhood Cancer700 Children’s DriveColumbus, OH 43205 (map)

Learn more about Meisam Naeimi Kararoudi

Research

Lab(s)

Center for Childhood Cancer

Dr. Naeimi Kararoudi is developing novel gene edited immune cells such as NK cells and T-cells for cancer immunotherapy. As director of the CRISPR/Gene editing core he helps investigators with their CRISPR gene editing in a verity of cells and applications. Publications

                  Naeimi Kararoudi M, Nagai Y, Elmas E, de Souza Fernandes Pereira M, Ali SA, Imus PH, Wethington D, Borrello IM, Lee DA, Ghiaur G. CD38 deletion of human primary NK cells eliminates daratumumab-induced fratricide and boosts their effector activity. Blood. 2020 Nov 19; 136: 2416-2427.

                


                  Naeimi Kararoudi M, Dolatshad H, Trikha P, Hussain SA, Elmas E, Foltz JA, Moseman JE, Thakkar A, Nakkula RJ, Lamb M, Chakravarti N, McLaughlin KJ, Lee DA. Generation of Knock-out Primary and Expanded Human NK Cells Using Cas9 Ribonucleoproteins. J Vis Exp. 2018 Jun 14;  

View More Publications

Biography

Meisam Naeimi Kararoudi, DVM, PhD, is a research assistant professor of pediatrics at The Ohio State University College of Medicine. He is also the director of CRISPR/Gene editing Core and a principal investigator in the Center for Childhood Cancer at Nationwide Children’s Hospital. He received his veterinary surgery degree from Iran. He obtained his PhD from the University of Perugia, Italy and was trained as an Erasmus scholar at the University of Oxford, UK. Being a veterinary surgeon, immunologist and genetic engineer brought him to Sweden where he used CRISPR/Cas9 to decrease rejection after transplantation of tissue engineered organs at Sahlgrenska University Hospital. During this period, he also worked in SciLifeLab as a visiting Post-Doc to use genetic modification in cancer-related projects. During his postdoc at Dr. Dean Lee’s laboratory, he developed a method to genetically modify the hard-to-transfect human Natural Killer cells using CRISPR, and identified novel approaches to enhance their cytotoxicity and to target cancers via chimeric antigen receptors.

Academic and Clinical Areas

Center for Childhood Cancer

Principal Investigator

Primary Department

Center for Childhood Cancer

Education

Date of Appointment at Nationwide Children’s Hospital: 10/02/2017

Postdoctoral Training

Nationwide Children’s Hospital

Date Completed: 12/31/2020

Graduate School

University of Perugia

Date Completed: 12/31/2017

Graduate School

University of Oxford

Date Completed: 12/31/2015

Medical School

Islamic Azad University, Tabriz Branch

Date Completed: 12/31/2011

Contact Information

Center for Childhood Cancer

Call us at: (614) 355-1613

                    700 Children's DriveColumbus, OH 43205 (map)

Contact Information

Call us at: (614) 355-1613

Center for Childhood Cancer700 Children’s DriveColumbus, OH 43205 (map)

Learn more about Meisam Naeimi Kararoudi

Contact Information

• Call us at:
• (614) 355-1613
• Center for Childhood Cancer700 Children’s DriveColumbus, OH 43205 (map)

Learn more about Meisam Naeimi Kararoudi

Research

Lab(s)

Center for Childhood Cancer

Dr. Naeimi Kararoudi is developing novel gene edited immune cells such as NK cells and T-cells for cancer immunotherapy. As director of the CRISPR/Gene editing core he helps investigators with their CRISPR gene editing in a verity of cells and applications. Publications

                  Naeimi Kararoudi M, Nagai Y, Elmas E, de Souza Fernandes Pereira M, Ali SA, Imus PH, Wethington D, Borrello IM, Lee DA, Ghiaur G. CD38 deletion of human primary NK cells eliminates daratumumab-induced fratricide and boosts their effector activity. Blood. 2020 Nov 19; 136: 2416-2427.

                


                  Naeimi Kararoudi M, Dolatshad H, Trikha P, Hussain SA, Elmas E, Foltz JA, Moseman JE, Thakkar A, Nakkula RJ, Lamb M, Chakravarti N, McLaughlin KJ, Lee DA. Generation of Knock-out Primary and Expanded Human NK Cells Using Cas9 Ribonucleoproteins. J Vis Exp. 2018 Jun 14;  

View More Publications

Research

Lab(s)

Center for Childhood Cancer

Dr. Naeimi Kararoudi is developing novel gene edited immune cells such as NK cells and T-cells for cancer immunotherapy. As director of the CRISPR/Gene editing core he helps investigators with their CRISPR gene editing in a verity of cells and applications. Publications

                  Naeimi Kararoudi M, Nagai Y, Elmas E, de Souza Fernandes Pereira M, Ali SA, Imus PH, Wethington D, Borrello IM, Lee DA, Ghiaur G. CD38 deletion of human primary NK cells eliminates daratumumab-induced fratricide and boosts their effector activity. Blood. 2020 Nov 19; 136: 2416-2427.

                


                  Naeimi Kararoudi M, Dolatshad H, Trikha P, Hussain SA, Elmas E, Foltz JA, Moseman JE, Thakkar A, Nakkula RJ, Lamb M, Chakravarti N, McLaughlin KJ, Lee DA. Generation of Knock-out Primary and Expanded Human NK Cells Using Cas9 Ribonucleoproteins. J Vis Exp. 2018 Jun 14;  

View More Publications

Research

Lab(s)

Center for Childhood Cancer

Dr. Naeimi Kararoudi is developing novel gene edited immune cells such as NK cells and T-cells for cancer immunotherapy. As director of the CRISPR/Gene editing core he helps investigators with their CRISPR gene editing in a verity of cells and applications. Publications

                  Naeimi Kararoudi M, Nagai Y, Elmas E, de Souza Fernandes Pereira M, Ali SA, Imus PH, Wethington D, Borrello IM, Lee DA, Ghiaur G. CD38 deletion of human primary NK cells eliminates daratumumab-induced fratricide and boosts their effector activity. Blood. 2020 Nov 19; 136: 2416-2427.

                


                  Naeimi Kararoudi M, Dolatshad H, Trikha P, Hussain SA, Elmas E, Foltz JA, Moseman JE, Thakkar A, Nakkula RJ, Lamb M, Chakravarti N, McLaughlin KJ, Lee DA. Generation of Knock-out Primary and Expanded Human NK Cells Using Cas9 Ribonucleoproteins. J Vis Exp. 2018 Jun 14;  

View More Publications

Lab(s)

Center for Childhood Cancer

Dr. Naeimi Kararoudi is developing novel gene edited immune cells such as NK cells and T-cells for cancer immunotherapy. As director of the CRISPR/Gene editing core he helps investigators with their CRISPR gene editing in a verity of cells and applications. Publications

                  Naeimi Kararoudi M, Nagai Y, Elmas E, de Souza Fernandes Pereira M, Ali SA, Imus PH, Wethington D, Borrello IM, Lee DA, Ghiaur G. CD38 deletion of human primary NK cells eliminates daratumumab-induced fratricide and boosts their effector activity. Blood. 2020 Nov 19; 136: 2416-2427.

                


                  Naeimi Kararoudi M, Dolatshad H, Trikha P, Hussain SA, Elmas E, Foltz JA, Moseman JE, Thakkar A, Nakkula RJ, Lamb M, Chakravarti N, McLaughlin KJ, Lee DA. Generation of Knock-out Primary and Expanded Human NK Cells Using Cas9 Ribonucleoproteins. J Vis Exp. 2018 Jun 14;  

View More Publications

Lab(s)

Center for Childhood Cancer

Dr. Naeimi Kararoudi is developing novel gene edited immune cells such as NK cells and T-cells for cancer immunotherapy. As director of the CRISPR/Gene editing core he helps investigators with their CRISPR gene editing in a verity of cells and applications.

Lab(s)

Center for Childhood Cancer

• Center for Childhood Cancer

                  Naeimi Kararoudi M, Nagai Y, Elmas E, de Souza Fernandes Pereira M, Ali SA, Imus PH, Wethington D, Borrello IM, Lee DA, Ghiaur G. CD38 deletion of human primary NK cells eliminates daratumumab-induced fratricide and boosts their effector activity. Blood. 2020 Nov 19; 136: 2416-2427.
  
  
  
                  Naeimi Kararoudi M, Dolatshad H, Trikha P, Hussain SA, Elmas E, Foltz JA, Moseman JE, Thakkar A, Nakkula RJ, Lamb M, Chakravarti N, McLaughlin KJ, Lee DA. Generation of Knock-out Primary and Expanded Human NK Cells Using Cas9 Ribonucleoproteins. J Vis Exp. 2018 Jun 14;  
  
  

View More Publications

• Naeimi Kararoudi M, Nagai Y, Elmas E, de Souza Fernandes Pereira M, Ali SA, Imus PH, Wethington D, Borrello IM, Lee DA, Ghiaur G. CD38 deletion of human primary NK cells eliminates daratumumab-induced fratricide and boosts their effector activity. Blood. 2020 Nov 19; 136: 2416-2427.
• Naeimi Kararoudi M, Dolatshad H, Trikha P, Hussain SA, Elmas E, Foltz JA, Moseman JE, Thakkar A, Nakkula RJ, Lamb M, Chakravarti N, McLaughlin KJ, Lee DA. Generation of Knock-out Primary and Expanded Human NK Cells Using Cas9 Ribonucleoproteins. J Vis Exp. 2018 Jun 14;

Biography

Meisam Naeimi Kararoudi, DVM, PhD, is a research assistant professor of pediatrics at The Ohio State University College of Medicine. He is also the director of CRISPR/Gene editing Core and a principal investigator in the Center for Childhood Cancer at Nationwide Children’s Hospital. He received his veterinary surgery degree from Iran. He obtained his PhD from the University of Perugia, Italy and was trained as an Erasmus scholar at the University of Oxford, UK. Being a veterinary surgeon, immunologist and genetic engineer brought him to Sweden where he used CRISPR/Cas9 to decrease rejection after transplantation of tissue engineered organs at Sahlgrenska University Hospital. During this period, he also worked in SciLifeLab as a visiting Post-Doc to use genetic modification in cancer-related projects. During his postdoc at Dr. Dean Lee’s laboratory, he developed a method to genetically modify the hard-to-transfect human Natural Killer cells using CRISPR, and identified novel approaches to enhance their cytotoxicity and to target cancers via chimeric antigen receptors.

Biography

Meisam Naeimi Kararoudi, DVM, PhD, is a research assistant professor of pediatrics at The Ohio State University College of Medicine. He is also the director of CRISPR/Gene editing Core and a principal investigator in the Center for Childhood Cancer at Nationwide Children’s Hospital. He received his veterinary surgery degree from Iran. He obtained his PhD from the University of Perugia, Italy and was trained as an Erasmus scholar at the University of Oxford, UK. Being a veterinary surgeon, immunologist and genetic engineer brought him to Sweden where he used CRISPR/Cas9 to decrease rejection after transplantation of tissue engineered organs at Sahlgrenska University Hospital. During this period, he also worked in SciLifeLab as a visiting Post-Doc to use genetic modification in cancer-related projects. During his postdoc at Dr. Dean Lee’s laboratory, he developed a method to genetically modify the hard-to-transfect human Natural Killer cells using CRISPR, and identified novel approaches to enhance their cytotoxicity and to target cancers via chimeric antigen receptors.

Biography

Meisam Naeimi Kararoudi, DVM, PhD, is a research assistant professor of pediatrics at The Ohio State University College of Medicine. He is also the director of CRISPR/Gene editing Core and a principal investigator in the Center for Childhood Cancer at Nationwide Children’s Hospital. He received his veterinary surgery degree from Iran. He obtained his PhD from the University of Perugia, Italy and was trained as an Erasmus scholar at the University of Oxford, UK. Being a veterinary surgeon, immunologist and genetic engineer brought him to Sweden where he used CRISPR/Cas9 to decrease rejection after transplantation of tissue engineered organs at Sahlgrenska University Hospital. During this period, he also worked in SciLifeLab as a visiting Post-Doc to use genetic modification in cancer-related projects. During his postdoc at Dr. Dean Lee’s laboratory, he developed a method to genetically modify the hard-to-transfect human Natural Killer cells using CRISPR, and identified novel approaches to enhance their cytotoxicity and to target cancers via chimeric antigen receptors.

Meisam Naeimi Kararoudi, DVM, PhD, is a research assistant professor of pediatrics at The Ohio State University College of Medicine. He is also the director of CRISPR/Gene editing Core and a principal investigator in the Center for Childhood Cancer at Nationwide Children’s Hospital. He received his veterinary surgery degree from Iran. He obtained his PhD from the University of Perugia, Italy and was trained as an Erasmus scholar at the University of Oxford, UK. Being a veterinary surgeon, immunologist and genetic engineer brought him to Sweden where he used CRISPR/Cas9 to decrease rejection after transplantation of tissue engineered organs at Sahlgrenska University Hospital. During this period, he also worked in SciLifeLab as a visiting Post-Doc to use genetic modification in cancer-related projects. During his postdoc at Dr. Dean Lee’s laboratory, he developed a method to genetically modify the hard-to-transfect human Natural Killer cells using CRISPR, and identified novel approaches to enhance their cytotoxicity and to target cancers via chimeric antigen receptors.

Meisam Naeimi Kararoudi, DVM, PhD, is a research assistant professor of pediatrics at The Ohio State University College of Medicine. He is also the director of CRISPR/Gene editing Core and a principal investigator in the Center for Childhood Cancer at Nationwide Children’s Hospital. He received his veterinary surgery degree from Iran. He obtained his PhD from the University of Perugia, Italy and was trained as an Erasmus scholar at the University of Oxford, UK. Being a veterinary surgeon, immunologist and genetic engineer brought him to Sweden where he used CRISPR/Cas9 to decrease rejection after transplantation of tissue engineered organs at Sahlgrenska University Hospital. During this period, he also worked in SciLifeLab as a visiting Post-Doc to use genetic modification in cancer-related projects. During his postdoc at Dr. Dean Lee’s laboratory, he developed a method to genetically modify the hard-to-transfect human Natural Killer cells using CRISPR, and identified novel approaches to enhance their cytotoxicity and to target cancers via chimeric antigen receptors.

Academic and Clinical Areas

Center for Childhood Cancer

Principal Investigator

Primary Department

Center for Childhood Cancer

Academic and Clinical Areas

Center for Childhood Cancer

Principal Investigator

Primary Department

Center for Childhood Cancer

Academic and Clinical Areas

Center for Childhood Cancer

Principal Investigator

Primary Department

Center for Childhood Cancer

Center for Childhood Cancer

Principal Investigator

Primary Department

Center for Childhood Cancer

• Center for Childhood Cancer
• Principal Investigator
• Primary Department
• Center for Childhood Cancer

Education

Date of Appointment at Nationwide Children’s Hospital: 10/02/2017

Postdoctoral Training

Nationwide Children’s Hospital

Date Completed: 12/31/2020

Graduate School

University of Perugia

Date Completed: 12/31/2017

Graduate School

University of Oxford

Date Completed: 12/31/2015

Medical School

Islamic Azad University, Tabriz Branch

Date Completed: 12/31/2011

Education

Date of Appointment at Nationwide Children’s Hospital: 10/02/2017

Postdoctoral Training

Nationwide Children’s Hospital

Date Completed: 12/31/2020

Graduate School

University of Perugia

Date Completed: 12/31/2017

Graduate School

University of Oxford

Date Completed: 12/31/2015

Medical School

Islamic Azad University, Tabriz Branch

Date Completed: 12/31/2011

Education

Date of Appointment at Nationwide Children’s Hospital: 10/02/2017

Postdoctoral Training

Nationwide Children’s Hospital

Date Completed: 12/31/2020

Graduate School

University of Perugia

Date Completed: 12/31/2017

Graduate School

University of Oxford

Date Completed: 12/31/2015

Medical School

Islamic Azad University, Tabriz Branch

Date Completed: 12/31/2011

Date of Appointment at Nationwide Children’s Hospital: 10/02/2017

Postdoctoral Training

Nationwide Children’s Hospital

Date Completed: 12/31/2020

Graduate School

University of Perugia

Date Completed: 12/31/2017

Graduate School

University of Oxford

Date Completed: 12/31/2015

Medical School

Islamic Azad University, Tabriz Branch

Date Completed: 12/31/2011

Date of Appointment at Nationwide Children’s Hospital: 10/02/2017

Postdoctoral Training

Nationwide Children’s Hospital

Date Completed: 12/31/2020

Graduate School

University of Perugia

Date Completed: 12/31/2017

Graduate School

University of Oxford

Date Completed: 12/31/2015

Medical School

Islamic Azad University, Tabriz Branch

Date Completed: 12/31/2011

Contact Information

Center for Childhood Cancer

Call us at: (614) 355-1613

                    700 Children's DriveColumbus, OH 43205 (map)

Contact Information

Center for Childhood Cancer

Call us at: (614) 355-1613

                    700 Children's DriveColumbus, OH 43205 (map)

Contact Information

Center for Childhood Cancer

Call us at: (614) 355-1613

                    700 Children's DriveColumbus, OH 43205 (map)

Center for Childhood Cancer

Call us at: (614) 355-1613

                    700 Children's DriveColumbus, OH 43205 (map)

Call us at: (614) 355-1613

                    700 Children's DriveColumbus, OH 43205 (map)

Call us at: (614) 355-1613

                    700 Children's DriveColumbus, OH 43205 (map)

• Call us at:
• (614) 355-1613
• 700 Children’s DriveColumbus, OH 43205 (map)